Linking Drugs to Obscure Illnesses: Lessons from Pure Red Cell Aplasia, Nephrogenic Systemic Fibrosis, and Reye’s Syndrome. A Report From the Southern Network on Adverse Reactions (SONAR)

[1]  I. Macdougall,et al.  Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. , 2012, Kidney international.

[2]  S. Xirasagar,et al.  Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease , 2012, Clinical kidney journal.

[3]  I. Macdougall,et al.  Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity , 2011, Pharmaceutical Research.

[4]  Tim Wogan.  Scientific publishing. A chilling effect? , 2010, Science.

[5]  H. Koplik.  The Diseases of Infancy and Childhood: Designed for the Use of Students and Practitioners of Medicine , 2010 .

[6]  L. E. Holt,et al.  The diseases of infancy and childhood : for the use of students and practitioners of medicine. , 2010 .

[7]  I. Macdougall,et al.  A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. , 2009, The New England journal of medicine.

[8]  M. Perazella.  Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm , 2009, Current opinion in nephrology and hypertension.

[9]  L. Skov,et al.  Nephrogenic systemic fibrosis: clinical picture and treatment. , 2009, Radiologic clinics of North America.

[10]  H. Thomsen,et al.  Nephrogenic systemic fibrosis: history and epidemiology. , 2009, Radiologic clinics of North America.

[11]  Allen R Nissenson,et al.  Epoetin‐associated pure red cell aplasia: past, present, and future considerations , 2008, Transfusion.

[12]  P. Marckmann.  An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital. , 2008, European journal of radiology.

[13]  D. Stenver.  Pharmacovigilance: what to do if you see an adverse reaction and the consequences. , 2008, European journal of radiology.

[14]  L. Skov,et al.  Case-control study of gadodiamide-related nephrogenic systemic fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  Lone Skov,et al.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.

[16]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  R. Bucala,et al.  Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis--setting the record straight. , 2006, Seminars in arthritis and rheumatism.

[18]  S. Belknap,et al.  Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. , 2005, Blood.

[19]  N. Casadevall,et al.  The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. , 2005, Kidney international.

[20]  G. Wells,et al.  Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. , 2004, Journal of the American Society of Nephrology : JASN.

[21]  Allen R Nissenson,et al.  Pure red-cell aplasia and epoetin therapy. , 2004, The New England journal of medicine.

[22]  Jeffrey B. Gross,et al.  Timing of New Black Box Warnings and Withdrawals for Prescription Medications , 2003 .

[23]  Patrick Mayeux,et al.  Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. , 2002, The New England journal of medicine.

[24]  P. Leboit,et al.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.

[25]  R. Holman,et al.  Reye's syndrome in the United States from 1981 through 1997. , 1999, The New England journal of medicine.

[26]  J. G. Kennedy.  Over the counter drugs , 1996, BMJ.

[27]  P. Buffler,et al.  Reduction of deaths after drug labelling for risk of Reye's syndrome , 1992, The Lancet.

[28]  A. Feinstein,et al.  New epidemiologic evidence confirming that bias does not explain the aspirin/Reye's syndrome association. , 1989, JAMA.

[29]  P. Pinsky,et al.  Reye's syndrome and aspirin. Evidence for a dose-response effect. , 1988 .

[30]  D. Kennedy,et al.  National patterns of aspirin use and Reye syndrome reporting, United States, 1980 to 1985. , 1987, Pediatrics.

[31]  P. Pinsky,et al.  Public Health Service study of Reye's syndrome and medications. Report of the main study. , 1987, JAMA.

[32]  M. Tarlow.  Reye's syndrome and aspirin. , 1986, British medical journal.

[33]  R. Kaslow,et al.  Public Health Service study on Reye's syndrome and medications. Report of the pilot phase. , 1985, The New England journal of medicine.

[34]  J. Glasgow.  Reye’s Syndrome , 1985, Drug safety.

[35]  F. Suchy,et al.  Grade I Reye's syndrome. A frequent cause of vomiting and liver dysfunction after varicella and upper-respiratory-tract infection. , 1983, The New England journal of medicine.

[36]  F. Mullick,et al.  HEPATIC AND CEREBRAL PATHOLOGY FINDINGS IN CHILDREN WITH FATAL SALICYLATE INTOXICATION: FURTHER EVIDENCE FOR A CAUSAL RELATION BETWEEN SALICYLATE AND REYE'S SYNDROME , 1983, The Lancet.

[37]  W. Glezen.  Aspirin and Reye's syndrome. , 1982, American journal of diseases of children.

[38]  R. Waldman,et al.  Aspirin as a risk factor in Reye's syndrome. , 1982, JAMA.

[39]  J. Cherry,et al.  Aspirin and Reye Syndrome , 1982, Pediatrics.

[40]  K. Starko,et al.  Reye's syndrome and salicylate use. , 1980, Pediatrics.

[41]  Moshe Y. Vardi,et al.  ACUTE DELIRIOUS STATE AFTER ϵ-AMINOCAPROIC ACID , 1978, The Lancet.

[42]  J. Korf,et al.  DOPAMINE AND SCHIZOPHRENIA , 1976, The Lancet.

[43]  G. Morley.  ASBESTOS IN THE AIR , 1976, The Lancet.

[44]  V. Hawthorne,et al.  SCREENING FOR DISEASE , 1975, The Lancet.

[45]  W. Schubert,et al.  Mitochondrial ultrastructure in Reye's syndrome (encephalopathy and fatty degeneration of the viscera). , 1971, The New England journal of medicine.

[46]  H. Giles.  ENCEPHALOPATHY AND FATTY DEGENERATION OF THE VISCERA. , 1965, Lancet.

[47]  R. Reye,et al.  ENCEPHALOPATHY AND FATTY DEGENERATION OF THE VISCERA , 1963 .

[48]  R. Reye,et al.  ENCEPHALOPATHY AND FATTY DEGENERATION OF THE VISCERA. A DISEASE ENTITY IN CHILDHOOD. , 1963, Lancet.

[49]  E. Mortimer,et al.  Varicella with hypoglycemia possibly due to salicylates. , 1962, American journal of diseases of children.

[50]  W. Segar,et al.  Physiologic abnormalities of salicylate intoxication. , 1958, The New England journal of medicine.

[51]  H. D. Riley,et al.  Salicylate intoxication. , 1956, Pediatrics.

[52]  K. Bain.  Death due to accidental poisoning in young children. , 1954, The Journal of pediatrics.

[53]  W. Parker,et al.  The toxic manifestations of sodium salicylate therapy. , 1948, The Quarterly journal of medicine.

[54]  Haub.  Salicylate intoxication in the infant and young child , 1947 .

[55]  R. Wégria,et al.  Salicylate therapy in acute rheumatic fever , 1945 .

[56]  F. Collins.  Diseases of Infancy and Childhood , 1938, The Indian Medical Gazette.

[57]  W. R. Brain,et al.  ACUTE MENINGO-ENCEPHALOMYELITIS OF CHILDHOOD. , 1929 .

[58]  P. Hanzlik.  A study of the toxicity of the salicylates based on clinical statistics , 1913 .

[59]  K. Eckardt,et al.  Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. , 2012, Clinical nephrology.

[60]  R. Campbell,et al.  Reye's syndrome and medication use. , 1982, JAMA.

[61]  Surgeon General's advisory on the use of salicylates and Reye syndrome. , 1982, MMWR. Morbidity and mortality weekly report.

[62]  Reye syndrome--Ohio, Michigan. , 1981, Connecticut medicine.